In its June 10, 2020, opinion in Nguyen v. Endologix, the U.S. Court of Appeals for the Ninth Circuit applied the plausibility standard to a plaintiff’s securities fraud claims and affirmed the district court’s dismissal,...more
6/25/2020
/ Appeals ,
Class Action ,
Clinical Trials ,
Dismissal With Prejudice ,
FDA Approval ,
Medical Devices ,
Motion to Dismiss ,
Plausibility Standard ,
Pleading Standards ,
Popular ,
PSLRA ,
Publicly-Traded Companies ,
Securities Fraud